Genmab As Stock Technical Analysis
| GMAB Stock | USD 30.97 0.93 2.92% |
As of the 6th of February, Genmab AS retains the Downside Deviation of 2.34, risk adjusted performance of 0.0555, and Market Risk Adjusted Performance of 0.1145. Genmab AS technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Genmab AS Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Genmab, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to GenmabGenmab AS's Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.Genmab AS Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 37.93 | Buy | 9 | Odds |
Most Genmab analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Genmab stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Genmab AS, talking to its executives and customers, or listening to Genmab conference calls.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. Market participants price Genmab higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Genmab AS assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 1.076 | Earnings Share 2.29 | Revenue Per Share | Quarterly Revenue Growth 0.174 | Return On Assets |
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Genmab AS's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Genmab AS 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Genmab AS's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Genmab AS.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in Genmab AS on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding Genmab AS or generate 0.0% return on investment in Genmab AS over 90 days. Genmab AS is related to or competes with Incyte, United Therapeutics, Royalty Pharma, Tenet Healthcare, Illumina, Quest Diagnostics, and Roivant Sciences. Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark More
Genmab AS Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Genmab AS's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Genmab AS upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.34 | |||
| Information Ratio | 0.0447 | |||
| Maximum Drawdown | 9.44 | |||
| Value At Risk | (3.42) | |||
| Potential Upside | 4.09 |
Genmab AS Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Genmab AS's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Genmab AS's standard deviation. In reality, there are many statistical measures that can use Genmab AS historical prices to predict the future Genmab AS's volatility.| Risk Adjusted Performance | 0.0555 | |||
| Jensen Alpha | 0.0894 | |||
| Total Risk Alpha | 0.0308 | |||
| Sortino Ratio | 0.0425 | |||
| Treynor Ratio | 0.1045 |
Genmab AS February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0555 | |||
| Market Risk Adjusted Performance | 0.1145 | |||
| Mean Deviation | 1.76 | |||
| Semi Deviation | 2.23 | |||
| Downside Deviation | 2.34 | |||
| Coefficient Of Variation | 1538.94 | |||
| Standard Deviation | 2.22 | |||
| Variance | 4.95 | |||
| Information Ratio | 0.0447 | |||
| Jensen Alpha | 0.0894 | |||
| Total Risk Alpha | 0.0308 | |||
| Sortino Ratio | 0.0425 | |||
| Treynor Ratio | 0.1045 | |||
| Maximum Drawdown | 9.44 | |||
| Value At Risk | (3.42) | |||
| Potential Upside | 4.09 | |||
| Downside Variance | 5.48 | |||
| Semi Variance | 4.96 | |||
| Expected Short fall | (1.75) | |||
| Skewness | (0.12) | |||
| Kurtosis | (0.29) |
Genmab AS Backtested Returns
At this point, Genmab AS is very steady. Genmab AS holds Efficiency (Sharpe) Ratio of 0.0573, which attests that the entity had a 0.0573 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Genmab AS, which you can use to evaluate the volatility of the firm. Please check out Genmab AS's Market Risk Adjusted Performance of 0.1145, risk adjusted performance of 0.0555, and Downside Deviation of 2.34 to validate if the risk estimate we provide is consistent with the expected return of 0.13%. Genmab AS has a performance score of 4 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 1.29, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Genmab AS will likely underperform. Genmab AS right now retains a risk of 2.31%. Please check out Genmab AS maximum drawdown, semi variance, and the relationship between the sortino ratio and potential upside , to decide if Genmab AS will be following its current trending patterns.
Auto-correlation | -0.01 |
Very weak reverse predictability
Genmab AS has very weak reverse predictability. Overlapping area represents the amount of predictability between Genmab AS time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Genmab AS price movement. The serial correlation of -0.01 indicates that just 1.0% of current Genmab AS price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.01 | |
| Spearman Rank Test | 0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 1.13 |
Genmab AS technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Genmab AS Technical Analysis
The output start index for this execution was fifty with a total number of output elements of eleven. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Genmab AS volatility. High ATR values indicate high volatility, and low values indicate low volatility.
About Genmab AS Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Genmab AS on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Genmab AS based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Genmab AS price pattern first instead of the macroeconomic environment surrounding Genmab AS. By analyzing Genmab AS's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Genmab AS's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Genmab AS specific price patterns or momentum indicators. Please read more on our technical analysis page.
| 2023 | 2024 | 2025 | 2026 (projected) | Days Sales Outstanding | 109.61 | 113.45 | 130.47 | 231.29 | PTB Ratio | 4.45 | 2.63 | 2.37 | 2.25 |
Genmab AS February 6, 2026 Technical Indicators
Most technical analysis of Genmab help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Genmab from various momentum indicators to cycle indicators. When you analyze Genmab charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0555 | |||
| Market Risk Adjusted Performance | 0.1145 | |||
| Mean Deviation | 1.76 | |||
| Semi Deviation | 2.23 | |||
| Downside Deviation | 2.34 | |||
| Coefficient Of Variation | 1538.94 | |||
| Standard Deviation | 2.22 | |||
| Variance | 4.95 | |||
| Information Ratio | 0.0447 | |||
| Jensen Alpha | 0.0894 | |||
| Total Risk Alpha | 0.0308 | |||
| Sortino Ratio | 0.0425 | |||
| Treynor Ratio | 0.1045 | |||
| Maximum Drawdown | 9.44 | |||
| Value At Risk | (3.42) | |||
| Potential Upside | 4.09 | |||
| Downside Variance | 5.48 | |||
| Semi Variance | 4.96 | |||
| Expected Short fall | (1.75) | |||
| Skewness | (0.12) | |||
| Kurtosis | (0.29) |
Genmab AS February 6, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Genmab stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 51,699 | ||
| Daily Balance Of Power | (0.85) | ||
| Rate Of Daily Change | 0.97 | ||
| Day Median Price | 31.49 | ||
| Day Typical Price | 31.32 | ||
| Price Action Indicator | (0.99) |
Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |